Dexpramipexole dihydrochloride is under clinical development by Areteia Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Dexpramipexole dihydrochloride’s likelihood of approval (LoA) and phase transition for Hypereosinophilic Syndrome took place on 18 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dexpramipexole dihydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Dexpramipexole dihydrochloride overview
Dexpramipexole dihydrochloride (BIIB050, KNS760704) is under development for the treatment of hypereosinophilic syndrome and eosinophilic asthma . The drug candidate is formulated as film coated tablet and administered through oral route. BIIB050 is the chirally pure form of dexpramipexole. It was also under development for amyotrophic lateral sclerosis (ALS) and chronic rhinosinusitis.
Areteia Therapeutics overview
Areteia Therapeutics is a biotechnology company developing dexpramipexole, an oral medicine that inhibits the maturation of eosinophils. Areteia Therapeutics is headquartered in Bernardsville, New Jersey, the US.
Quick View Dexpramipexole dihydrochloride LOA Data
|Highest Development Stage|